Abstract
Infants undergoing surgery for congenital heart disease are at risk for myocardial ischemia during cardiopulmonary bypass, circulatory arrest, or low-flow states. The purpose of this study was to demonstrate the effects of sildenafil, a selective phosphodiesterase-5 (PDE-5) inhibitor on myocardial functional improvement and infarct size reduction during ischemia/reperfusion injury in infant rabbits. Infant rabbits (aged 8 wk) were treated with sildenafil citrate (0.7 mg/kg i.v.) or normal saline 30 min before sustained ischemia for 30 min and reperfusion for 3 h. Transesophageal echocardiography (TEE) was used to assess left ventricular cardiac output (LVCO) and aortic velocity time integral (VTI). After ischemia/reperfusion, risk area was demarcated by Evan's blue dye and infarct size determined by computer morphometry of triphenyltetrazolium chloride–stained sections. The sildenafil-treated group had preservation and elevation in LVCO (143% of baseline, p < 0.05) and an elevated aortic VTI (145% of baseline, p < 0.05) after 30 min of ischemia compared with the control group LVCO (72% of baseline, p < 0.05) and aortic VTI (73% of baseline, p < 0.05). This is a statistically significant increase in LVCO and aortic VTI in the sildenafil group compared with controls (n = 6/group, p < 0.05). The sildenafil-treated group had significant reduction in infarct size (15.5 ± 1.2 versus 33 ± 2.3 in the saline group, % risk area, mean ± SEM, n = 10–15/group, p < 0.05). For the first time, we have shown that sildenafil citrate promotes myocardial protection in infant rabbits as evidenced by postischemic preservation and elevation in LVCO and aortic VTI and reduction in infarct size.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- HR:
-
heart rate
- LAD:
-
left anterior descending
- LV:
-
left ventricle
- LVCO:
-
left ventricular cardiac output
- LVOT:
-
left ventricular outflow tract
- MAP:
-
mean arterial pressure
- PDE-5:
-
phosphodiesterase-5
- SVR:
-
systemic vascular resistance
- TEE:
-
transesophageal echocardiography
- TTC:
-
2,3,5-triphenyltetrazolium chloride
- VTI:
-
velocity time integral
References
Rafiee P, Shi Y, Pritchard KA Jr Ogawa H, Eis AL, Komorowski RA, Fitzpatrick CM, Tweddell JS, Litwin SB, Mussatto K, Jaquiss RD, Baker JE 2003 Cellular redistribution of inducible Hsp70 protein in the human and rabbit heart in response to the stress of chronic hypoxia: role of protein kinases. J Biol Chem 278: 43636–43644
Long WA, Kirklin JK 1990 Neonatal cardiopulmonary bypass. In: Lamsback WJ (ed) Fetal and Neonatal Cardiology. WB Saunders, Philadelphia, pp 736–741
Lewin MB, Dreyer WJ, Fisher DJ 1998 Pathophysiology of ischemic myocardial injury and methods of myocardial protection. In: Garson A Jr, Bricker JT, Fisher DJ, Neish SR (eds) The Science and Practice of Pediatric Cardiology, 2nd Ed. Williams & Wilkins, Baltimore pp 279–295
Wernovsky G, Chang AC, Wessel DL 2001 Intensive care. In: Allen HD, Gutgesell HP, Clark EB, Driscoll DJ (eds) Moss and Adams' Heart Disease in Infants, Children, and Adolescents Including the Fetus and the Young Adult, 6th Ed. Lippincott Williams & Wilkins, Philadelphia pp 350–381
Baker JE, Boerboom LE, Olinger GN 1988 Age-related changes in the ability of hypothermia and cardioplegia to protect ischemic rabbit myocardium. J Thorac Cardiovasc Surg 96: 717–724
Murry CE, Jennings RB, Reimer KA 1986 Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124–1136
Xi L, Tekin D, Gursoy E, Salloum F, Levasseur JE, Kukreja RC 2002 Evidence that NOS2 acts as a trigger and mediator of late preconditioning induced by acute systemic hypoxia. Am J Physiol Heart Circ Physiol 283: H5–H12
Xi L, Tekin D, Bhargava P, Kukreja RC 2001 Whole body hypothermia and preconditioning of the heart: basic concepts, complexity and potential mechanisms. Int J Hyperthermia 17: 439–455
Zhao T, Xi L, Chelliah J, Levasseur JE, Kukreja RC 2000 Inducible nitric oxide synthase mediates delayed myocardial protection induced by activation of adenosine A1 receptors: evidence from gene-knockout mice. Circulation 102: 902–907
Kositprapa C, Ockaili RA, Kukreja RC 2001 Bradykinin B2 receptor is involved in the late phase of preconditioning in rabbit heart. J Mol Cell Cardiol 33: 1355–1362
Ockaili R, Salloum F, Hawkins J, Kukreja RC 2002 Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial KATP channel in rabbits. Am J Physiol Heart Circ Physiol 283: H1263–H1269
Kimball TR, Meyer RA 2001 Echocardiography. In: Allen HD, Gutgesell HP, Clark EB, Driscoll DJ (eds) Moss and Adams' Heart Disease in Infants, Children, and Adolescents Including the Fetus and the Young Adult, 6th Ed. Lippincott Williams & Wilkins, Philadelphia pp 204–233
Snider AR, Serwer GA 1990 Methods for obtaining quantitative information from the echocardiographic examination. In: Lampert RH, Thorp D (eds) Echocardiography in Pediatric Heart Disease. Mosby-Year Book, St. Louis Echocardiography in Pediatric Heart Disease. pp 78–133
Gillies HC, Roblin D, Jackson G 2002 Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int J Cardiol 86: 131–141
Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR 2003 Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107: 3230–3235
Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW 2001 Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104: 1218–1222
Stiebellehner L, Petkov V, Vonbank K, Funk G, Schenk P, Ziesche R, Block LH 2003 Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 123: 1293–1295
Kukreja RC, Ockaili R, Salloum F, Yin C, Hawkins J, Das A, Xi L 2004 Cardioprotection with phosphodiesterase-5 inhibition—a novel preconditioning strategy. J Mol Cell Cardiol 36: 165–173
Salloum F, Yin C, Xi L, Kukreja RC 2003 Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 92: 595–597
Das A, Ockaili R, Salloum F, Kukreja RC 2004 Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. Am J Physiol Heart Circ Physiol 286: H1455–H1460
Snider AR, Ritter SB 2001 Doppler echocardiography. In: Allen HD, Gutgesell HP, Clark EB, Driscoll DJ (eds) Moss and Adams' Heart Disease in Infants, Children, and Adolescents Including the Fetus and the Young Adult, 6th Ed. Lippincott Williams & Wilkins, Philadelphia pp 234–263
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported, in part, by Grants HL 51045 and HL-59469 from the National Institutes of Health (R.C.K.).
Rights and permissions
About this article
Cite this article
Bremer, Y., Salloum, F., Ockaili, R. et al. Sildenafil Citrate (Viagra) Induces Cardioprotective Effects after Ischemia/Reperfusion Injury in Infant Rabbits. Pediatr Res 57, 22–27 (2005). https://doi.org/10.1203/01.PDR.0000147736.27672.15
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/01.PDR.0000147736.27672.15
This article is cited by
-
Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy
Inflammation (2016)
-
The protective effects of a phosphodiesterase 5 inhibitor, sildenafil, on postresuscitation cardiac dysfunction of cardiac arrest: metabolic evidence from microdialysis
Critical Care (2014)
-
Tadalafil Prevents Acute Heart Failure with Reduced Ejection Fraction in Mice
Cardiovascular Drugs and Therapy (2014)
-
PDE5A suppression of acute β-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation
Basic Research in Cardiology (2010)
-
Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts
Acta Pharmacologica Sinica (2009)
